We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

54 hedge funds and large institutions have $41.1M invested in Matinas BioPharma in 2019 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

399% more capital invested

Capital invested by funds: $8.24M → $41.1M (+$32.9M)

380% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 5

54% more funds holding

Funds holding: 35 → 54 (+19)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

0.29% more ownership

Funds ownership: 0.25% → 0.54% (+0.29%)

Holders
54
Holders Change
+19
Holders Change %
+54.29%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
10
Reduced
8
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$7.34M
2
BC
Boxer Capital
California
+$4.9M
3
BC
Broadfin Capital
New York
+$2.94M
4
SCM
Stonepine Capital Management
Oregon
+$2.16M
5
Victory Capital Management
Victory Capital Management
Texas
+$1.85M

Top Sellers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
-$1.08M
2
AGM
Alpine Global Management
New York
-$245K
3
Citadel Advisors
Citadel Advisors
Florida
-$61K
4
RJFSA
Raymond James Financial Services Advisors
Florida
-$51.7K
5
Squarepoint
Squarepoint
New York
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$66K +$65.1K +1,208 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$61K -$1.83K -34 -3%
PAG
28
Private Advisor Group
New Jersey
$55K +$539 +10 +1%
BJL
29
Brighton Jones LLC
Washington
$55K +$53.9K +1,000 New
JP Morgan Chase
30
JP Morgan Chase
New York
$49K – – –
IIA
31
IPG Investment Advisors
California
$46.3K +$16.2K +300 +55%
Jane Street
32
Jane Street
New York
$45K +$29.2K +543 +190%
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$43K -$4.79K -89 -10%
ECM
34
ExodusPoint Capital Management
New York
$42K +$41.1K +764 New
Charles Schwab
35
Charles Schwab
California
$39K +$37.8K +702 New
Bank of America
36
Bank of America
North Carolina
$34K +$33.5K +622 New
JMPWA
37
JP Morgan Private Wealth Advisors
California
$33K – – –
Wells Fargo
38
Wells Fargo
California
$28K +$5.39K +100 +24%
LTFS
39
Ladenburg Thalmann Financial Services
Florida
$27K – – –
NRS
40
Neville Rodie & Shaw
New York
$19K – – –
Commonwealth Equity Services
41
Commonwealth Equity Services
Massachusetts
$17K +$6.46K +120 +59%
UBS Group
42
UBS Group
Switzerland
$12K -$13.6K -252 -54%
USAA
43
United Services Automobile Association
Texas
$12K – – –
CFS
44
CRA Financial Services
New Jersey
$11K – – –
FC
45
Fore Capital
New York
$11K – – –
AIC
46
Ameritas Investment Company
Nebraska
$6K +$6.03K +112 New
AG
47
Advisor Group
Arizona
$4K +$4.31K +80 New
HFM
48
Hartford Financial Management
Connecticut
$3K – – –
CHP
49
Cable Hill Partners
Oregon
$1K -$9.7K -180 -90%
Morgan Stanley
50
Morgan Stanley
New York
$1K -$1.08K -20 -50%
1
2
3

MTNB Hedge Fund Activity: Q1 2019 in Review

54 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2019, worth a combined $41.1M — up 399% from $8.24M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new MTNB positions and 5 closed out — a net gain of 19 holders — while 10 added to existing stakes and 8 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $7.34M. The largest seller was IFP Advisors, exiting entirely with an estimated $1.08M sold.

  • 54 institutional investors held Matinas BioPharma (MTNB) as of Q1 2019, up from 35 in Q4 2018.
  • Funds reported $41.1M of Matinas BioPharma stock for Q1 2019, up 399% quarter-over-quarter.
  • 24 funds opened new Matinas BioPharma positions in Q1 2019 and 5 closed out, a net change of +19 holders.
  • The largest Matinas BioPharma buyer in Q1 2019 was Vivo Capital, an estimated $7.34M added.
  • The largest Matinas BioPharma seller in Q1 2019 was IFP Advisors, an estimated $1.08M sold.

Based on aggregated 13F filings for Q1 2019.